4-aminopyridine has been researched along with Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in 1 studies
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: A slowly progressive autoimmune demyelinating disease of peripheral nerves and nerve roots. Clinical manifestations include weakness and sensory loss in the extremities and enlargement of peripheral nerves. The course may be relapsing-remitting or demonstrate a step-wise progression. Protein is usually elevated in the spinal fluid and cranial nerves are typically spared. GUILLAIN-BARRE SYNDROME features a relatively rapid progression of disease which distinguishes it from this condition. (Adams et al., Principles of Neurology, 6th ed, p1337)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leussink, VI | 1 |
| Stettner, M | 1 |
| Warnke, C | 1 |
| Hartung, HP | 1 |
1 other study available for 4-aminopyridine and Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
| Article | Year |
|---|---|
Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system.
Topics: 4-Aminopyridine; Disability Evaluation; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Po | 2016 |